241 related articles for article (PubMed ID: 23903772)
1. Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment.
Donnelly LA; van Zuydam NR; Zhou K; Tavendale R; Carr F; Maitland-van der Zee AH; Leusink M; de Boer A; Doevendans PA; Asselbergs FW; Morris AD; Pearson ER; Klungel OH; Doney AS; Palmer CN
Pharmacogenet Genomics; 2013 Oct; 23(10):518-25. PubMed ID: 23903772
[TBL] [Abstract][Full Text] [Related]
2. LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins.
Wei WQ; Li X; Feng Q; Kubo M; Kullo IJ; Peissig PL; Karlson EW; Jarvik GP; Lee MTM; Shang N; Larson EA; Edwards T; Shaffer CM; Mosley JD; Maeda S; Horikoshi M; Ritchie M; Williams MS; Larson EB; Crosslin DR; Bland HT; Pacheco JA; Rasmussen-Torvik LJ; Cronkite D; Hripcsak G; Cox NJ; Wilke RA; Stein CM; Rotter JI; Momozawa Y; Roden DM; Krauss RM; Denny JC
Circulation; 2018 Oct; 138(17):1839-1849. PubMed ID: 29703846
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study.
Donnelly LA; Palmer CN; Whitley AL; Lang CC; Doney AS; Morris AD; Donnan PT
Pharmacogenet Genomics; 2008 Apr; 18(4):279-87. PubMed ID: 18334912
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.
Voora D; Shah SH; Reed CR; Zhai J; Crosslin DR; Messer C; Salisbury BA; Ginsburg GS
Circ Cardiovasc Genet; 2008 Dec; 1(2):100-6. PubMed ID: 20031551
[TBL] [Abstract][Full Text] [Related]
5. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
Sampalis JS; Bissonnette S; Habib R; Boukas S;
Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579
[TBL] [Abstract][Full Text] [Related]
6. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study.
Donnelly LA; Doney AS; Dannfald J; Whitley AL; Lang CC; Morris AD; Donnan PT; Palmer CN
Pharmacogenet Genomics; 2008 Dec; 18(12):1021-6. PubMed ID: 18815589
[TBL] [Abstract][Full Text] [Related]
7. Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
Lotta LA; Sharp SJ; Burgess S; Perry JRB; Stewart ID; Willems SM; Luan J; Ardanaz E; Arriola L; Balkau B; Boeing H; Deloukas P; Forouhi NG; Franks PW; Grioni S; Kaaks R; Key TJ; Navarro C; Nilsson PM; Overvad K; Palli D; Panico S; Quirós JR; Riboli E; Rolandsson O; Sacerdote C; Salamanca EC; Slimani N; Spijkerman AM; Tjonneland A; Tumino R; van der A DL; van der Schouw YT; McCarthy MI; Barroso I; O'Rahilly S; Savage DB; Sattar N; Langenberg C; Scott RA; Wareham NJ
JAMA; 2016 Oct; 316(13):1383-1391. PubMed ID: 27701660
[TBL] [Abstract][Full Text] [Related]
8. HDL-C: role as a risk modifier.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
[TBL] [Abstract][Full Text] [Related]
9. Investigation of LPA sequence variants rs6415084, rs3798220 with conventional coronary artery disease in Iranian CAD patients.
Rouhani B; Ghaderian SMH; Salehi Z
Hum Antibodies; 2019; 27(2):99-104. PubMed ID: 30594920
[TBL] [Abstract][Full Text] [Related]
10. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.
Damask A; Steg PG; Schwartz GG; Szarek M; Hagström E; Badimon L; Chapman MJ; Boileau C; Tsimikas S; Ginsberg HN; Banerjee P; Manvelian G; Pordy R; Hess S; Overton JD; Lotta LA; Yancopoulos GD; Abecasis GR; Baras A; Paulding C;
Circulation; 2020 Feb; 141(8):624-636. PubMed ID: 31707832
[TBL] [Abstract][Full Text] [Related]
11. Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry.
Xian Y; Navar AM; Li S; Li Z; Robinson J; Virani SS; Louie MJ; Koren A; Goldberg A; Roger VL; Wilson PWF; Peterson ED; Wang TY
J Am Heart Assoc; 2019 Oct; 8(19):e013229. PubMed ID: 31554462
[TBL] [Abstract][Full Text] [Related]
12. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy.
Shishehbor MH; Aviles RJ; Brennan ML; Fu X; Goormastic M; Pearce GL; Gokce N; Keaney JF; Penn MS; Sprecher DL; Vita JA; Hazen SL
JAMA; 2003 Apr; 289(13):1675-80. PubMed ID: 12672736
[TBL] [Abstract][Full Text] [Related]
13. Validation and quantification of genetic determinants of lipoprotein-a levels and predictive value for angiographic coronary artery disease.
Anderson JL; Knight S; May HT; Horne BD; Bair TL; Huntinghouse JA; Rollo JS; Muhlestein JB; Carlquist JF
Am J Cardiol; 2013 Sep; 112(6):799-804. PubMed ID: 23735648
[TBL] [Abstract][Full Text] [Related]
14. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
[TBL] [Abstract][Full Text] [Related]
15. Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression.
Masson W; Lobo M; Siniawski D; Molinero G; Masson G; Huerín M; Nogueira JP
Lipids Health Dis; 2020 May; 19(1):111. PubMed ID: 32460779
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study.
Ford I; Murray H; McCowan C; Packard CJ
Circulation; 2016 Mar; 133(11):1073-80. PubMed ID: 26864092
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review.
Gudzune KA; Monroe AK; Sharma R; Ranasinghe PD; Chelladurai Y; Robinson KA
Ann Intern Med; 2014 Apr; 160(7):468-76. PubMed ID: 24514899
[TBL] [Abstract][Full Text] [Related]
18. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
[TBL] [Abstract][Full Text] [Related]
19. Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials.
Lee M; Cheng CY; Wu YL; Lee JD; Hsu CY; Ovbiagele B
JAMA Neurol; 2022 Apr; 79(4):349-358. PubMed ID: 35188949
[TBL] [Abstract][Full Text] [Related]
20. Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?
Ruaño G; Thompson PD; Kane JP; Pullinger CR; Windemuth A; Seip RL; Kocherla M; Holford TR; Wu AH
Pharmacogenomics; 2010 Jul; 11(7):959-71. PubMed ID: 20602615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
